Preferred Label : Pirtobrutinib;
NCIt synonyms : BTK Inhibitor LOXO-305; 5-Amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-((2S)-1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamide;
NCIt definition : An orally available, selective, non-covalent Bruton's tyrosine kinase (BTK) inhibitor
with potential antineoplastic activity. Upon oral administration, pirtobrutinib selectively
and reversibly binds to BTK. This prevents both the activation of the B-cell antigen
receptor (BCR) signaling pathway and BTK-mediated activation of downstream survival
pathways, thereby inhibiting the growth of malignant B-cells that overexpress BTK.
Reversible binding of LOXO-305 may preserve antitumor activity in the presence of
certain acquired resistance mutations, including C481 mutated BTK, and limit toxicity
associated with inhibition of other non-BTK kinases. BTK, a member of the Src-related
BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed or mutated in B-cell
malignancies; it plays an important role in the development, activation, signaling,
proliferation and survival of B-lymphocytes.;
UNII : JNA39I7ZVB;
CAS number : 2101700-15-4; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 2101700-15-4
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Drug name : Jaypirca;
Molecule name : LOXO-305; LOXO 305; LY3527727;
NCI Metathesaurus CUI : CL950650;
Codes from synonyms : 61419;
Origin ID : C158617;
UMLS CUI : C5554559;
Currated CISMeF NLP mapping
- Semantic type(s)
- UMLS correspondences (same concept)
- concept_is_in_subset
- has_target
- is_component_of_chemotherapy_regimen
